Compare Conagra Brands Inc (CAG) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Conagra Brands Inc vs ResMed Inc. — how do they compare? Conagra Brands Inc trades at $15.04 (market cap $7.14B), while ResMed Inc. trades at $225.82 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 4.6× Conagra Brands Inc's market cap, and Conagra Brands Inc pays the higher dividend (8.2%). Which is the better fit depends on your goals.
| CAG | RMD | |
|---|---|---|
Market Cap | $7.14B | $32.61B |
Sector | Consumer Staples | Health |
52-Week High | $20.02 | $293.73 |
52-Week Low | $12.58 | $182.82 |
Enterprise Value | $14.20B | $31.97B |
Dividend Yield | 8.2% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Conagra Brands (CAG) trades at $14.985, up 1.39% with neutral technical signals. The company shows mixed fundamentals with a P/E of 10.06 and P/S of 0.63 suggesting undervaluation, but negative net income margin (-16.99%) and ROE (-25.06%) reflect profitability challenges. Recent earnings show two beats and one miss in the last four quarters, with Q3 2026 results pending. The company recently cut its dividend by 50% to prioritize debt reduction and operational improvements under new CEO John Brase.
CAG presents a turnaround story with attractive valuation metrics but faces significant headwinds including declining sales, margin pressure, and high debt levels. Analyst consensus is cautious with 62.5% hold ratings and a $13.67 price target below current levels. The dividend cut provides financial flexibility but signals ongoing challenges. Investors should weigh the discounted valuation against persistent operational pressures and weak growth outlook.
ResMed (RMD) trades at $225.17, up 2.33% today, reflecting strong recent earnings beats and robust fundamentals. The stock exhibits a bullish technical trend, supported by positive moving averages, with key resistance near $227. Financially, the company shows impressive growth, with Q4 2026 revenue reaching a record $1.5 billion (Reuters, 2026-08-07) and a net income margin of 26.94%. Recent strategic moves include the divestiture of the MatrixCare business to sharpen focus on core sleep and respiratory care markets.
The outlook for RMD is positive, driven by consistent earnings outperformance and strategic portfolio optimization. However, investors face risks from weaker-than-expected fiscal 2027 revenue guidance and competitive pressures in the medtech sector. The consensus price target of $235.00 (MarketBeat, 2026-08-09) suggests modest upside potential, supported by a majority analyst hold rating amid solid long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Conagra Brands Inc
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
